22 Jul Endsulin
Hans Sollinger, M.D., Ph.D., Founder and Chief Science Officer
Oct. 14 | 9:45am | BlueRock Therapeutics Ballroom
Endsulin is a preclinical gene therapy company focused on advancing its lead clinical candidate to treat Diabetes mellitus. Endsulin’s novel technology aims to give millions of people greater euglycemic control by combining the extensively tested AAV8 platform with a patented liver-directed gene construct. The construct contains a regulatory element to precisely regulate insulin expression in response to fluctuating glucose levels in the blood. Founded by Dr. Hans Sollinger, a world-renowned kidney and pancreas transplant surgeon, Endsulin established operations in 2020. The company’s technology is based on decades of research by Dr. Sollinger’s team at the University of Wisconsin Hospitals and Clinics. Endsulin is led by an experienced team at the forefront of diabetes, gene therapy, and product development. Our mission is to create a life-changing treatment for diabetes that allows patients, families, and caregivers to live free from the restrictions, disruptions, limitations, and burdens associated with the disease.